Rheumatoid Arthritis: Sirukumab effective in patients refractory to anti-TNF therapy

Nature Reviews Rheumatology 13, 197 (2017).
doi:10.1038/nrrheum.2017.31

Author: Jessica McHugh
In the phase III SIRROUND-T study, treatment with the IL-6-specific antibody sirukumab was well tolerated and showed clinical efficacy in patients with RA refractory to anti-TNF therapy. At week 16, 40% (117 of 292) of patients treated with 50 mg sirukumab every 4 weeks and

Source: Nature Reviews Rheumatology - March 2, 2017 Category: Rheumatology Authors: Jessica McHugh Tags: Research Highlight Source Type: research